Drug Trial Radar · NCT04528355
Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Aug 20, 2020
Primary completion
Dec 31, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Paul SzabolcsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 27, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 months, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft failure and to aid in immune reconstitution following hematopoietic stem cell transplantation.
Conditions
- Primary Immunodeficiency (PID)
- Congenital Bone Marrow Failure Syndromes
- Inherited Metabolic Disorders (IMD)
- Hereditary Anemias
- Inflammatory Conditions
Interventions
data collectionDrug
Study subjects will receive alemtuzumab, melphalan, thiotepa, fludarabine and hydroxyurea-based, reduced-intensity conditioning regimen in accordance with clinical practice at UPMC Children's Hospital of Pittsburgh at the discretion of the treating physician. Medical data will be abstracted from subject's medical charts once the patient signs the informed consent.
Primary outcomes
What the sponsor says the trial is designed to measure.
- incidence of acute graft versus host disease (GVHD)Time frame: up to 5 years
- overall survival after HSCTTime frame: up to 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.